That’s what analysts think Marrone Bio Innovations, Inc. (NASDAQ:MBII) is worth after these results

Marrone Bio Innovations, Inc. (NASDAQ: MBII) missed earnings with its latest third-quarter results, disappointing overly optimistic forecasters. Unfortunately, Marrone Bio Innovations suffered a serious shortfall. Revenue of US$8.8 million was 15% below expectations and statutory losses jumped 41% to US$0.04 per share. Following the result, analysts have updated their earnings model, and it would be good to know if they think there has been a strong change in the company’s outlook, or if business is as it is. habit. With that in mind, we’ve rounded up the latest statutory forecasts to see what analysts expect for next year.

See our latest analysis for Marrone Bio Innovations



Given the latest results, the current consensus of Marrone Bio Innovations’ six analysts is for revenue of $59.0 million in 2021, which would reflect a substantial 58% increase in sales over the past 12 month. The loss per share is expected to decline sharply in the near future, narrowing 51% to US$0.088. Prior to this latest report, consensus had expected revenue of $60.6 million and losses of $0.083 per share. Overall, it looks like analysts are negative in this update. Although the sales forecast remained stable, the consensus also made a change to its forecast for losses per share.

The average price target rose 11% to US$1.98, a clear signal that lower earnings and EPS outlook should not weigh on the stock in the long term. It might also be instructive to look at the range of analysts’ estimates, to gauge how different the outlier opinions are from the mean. There are variant perceptions on Marrone Bio Innovations, with the most bullish analyst pricing it at $2.50 and the most bearish at $1.20 per share. Notice the wide gap between analyst price targets? This implies to us that there is a fairly wide range of possible scenarios for the underlying activity.

Looking at the big picture, one way to make sense of these forecasts is to see how they compare to both past performance and industry growth estimates. It is clear from the latest estimates that Marrone Bio Innovations’ growth rate is set to accelerate significantly, with projected revenue growth of 58% significantly faster than its historical growth of 26% per year over the past five years. . Compare that with other companies in the same industry, which are expected to increase revenue by 5.5% next year. It seems clear that while growth prospects are brighter than in the recent past, analysts also expect Marrone Bio Innovations to grow faster than the industry at large.

The essential

The most important thing to remember is that analysts have raised their loss per share estimates for next year. They also lowered their revenue estimates, although industry data suggests Marrone Bio Innovations revenue is expected to grow faster than the overall industry. There was also a nice rise in the price target, with analysts clearly sensing that the company’s intrinsic value is improving.

That said, the company’s long-term earnings trajectory is much more important than next year. At Simply Wall St, we have a full range of analyst estimates for Marrone Bio Innovations out to 2024, and you can see them for free on our platform here..

However, you should always think about the risks. Concrete example, we spotted 3 warning signs for Marrone Bio Innovations you should be aware.

This Simply Wall St article is general in nature. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial [email protected]